Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SIGA 
SIGA Technologies Inc (SIGA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: SIGA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -28.24% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 461.51M USD | Price to earnings Ratio 9.64 | 1Y Target Price 17.53 |
Price to earnings Ratio 9.64 | 1Y Target Price 17.53 | ||
Volume (30-day avg) - | Beta 0.95 | 52 Weeks Range 4.48 - 11.62 | Updated Date 06/29/2025 |
52 Weeks Range 4.48 - 11.62 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.67 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 40.33% | Operating Margin (TTM) -32.03% |
Management Effectiveness
Return on Assets (TTM) 14.4% | Return on Equity (TTM) 25.47% |
Valuation
Trailing PE 9.64 | Forward PE 9.81 | Enterprise Value 300868611 | Price to Sales(TTM) 3.84 |
Enterprise Value 300868611 | Price to Sales(TTM) 3.84 | ||
Enterprise Value to Revenue 2.5 | Enterprise Value to EBITDA 5.28 | Shares Outstanding 71441104 | Shares Floating 40427794 |
Shares Outstanding 71441104 | Shares Floating 40427794 | ||
Percent Insiders 43.29 | Percent Institutions 51.72 |
Upturn AI SWOT
SIGA Technologies Inc
Company Overview
History and Background
SIGA Technologies Inc. was founded in 1995. It focuses on developing solutions for serious infectious diseases and emerging chemical, biological, radiological, and nuclear (CBRN) threats. Significant milestones include the FDA approval of Tpoxxu00ae (tecovirimat) and government contracts for its supply.
Core Business Areas
- Biodefense: Development and commercialization of pharmaceutical solutions for CBRN threats, primarily focused on smallpox. Tpoxx is its flagship product.
Leadership and Structure
Phil Gomez is the CEO. The company has a board of directors and operates with distinct functional departments like R&D, manufacturing, and sales.
Top Products and Market Share
Key Offerings
- Tpoxx (Tecovirimat): Tpoxx is an antiviral drug approved for the treatment of smallpox. It is primarily sold to governments under contracts. SIGA has a virtual monopoly for an approved smallpox treatment. Competitors are non-approved treatments or vaccine manufacturers.
Market Dynamics
Industry Overview
The industry focuses on biodefense and emerging infectious diseases. Government contracts are crucial for revenue. Increased awareness of global health security risks is driving demand.
Positioning
SIGA is a leader in the development and supply of smallpox therapeutics, especially Tpoxx. The sole manufacturer with FDA approval, gives them a significant competitive advantage.
Total Addressable Market (TAM)
The TAM is difficult to quantify precisely but includes government biodefense spending globally related to poxvirus threats and emerging infectious diseases. Tpoxx is well positioned.
Upturn SWOT Analysis
Strengths
- FDA-approved drug (Tpoxx)
- Government contracts
- Strong IP protection
- Established manufacturing capabilities
Weaknesses
- Reliance on government contracts
- Single product focus
- Limited commercial market outside biodefense
- Vulnerable to generic competition if patents expire
Opportunities
- Expanding Tpoxx's use for other orthopoxviruses
- Developing new products for other biodefense threats
- Securing new government contracts
- Partnerships for distribution and commercialization
Threats
- Loss of government contracts
- Competition from alternative treatments
- Patent expiration
- Changes in government biodefense priorities
Competitors and Market Share
Key Competitors
- Emergent BioSolutions (EBS)
- Bavarian Nordic (no US listing)
Competitive Landscape
SIGA has an advantage due to Tpoxx's FDA approval. Competitors focus on vaccines or alternative treatments. Emergent Biosolutions is the biggest threat.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is driven primarily by government contracts and Tpoxx sales.
Future Projections: Future growth is expected to be driven by continued government procurement of Tpoxx and potential expansion into new markets.
Recent Initiatives: Recent strategic initiatives include securing new government contracts and pursuing regulatory approvals for expanded indications.
Summary
SIGA Technologies is a key player in biodefense, primarily due to its FDA-approved Tpoxx. Its reliance on government contracts presents a concentration risk, but the continuous threat of smallpox provides a stable revenue stream. Future growth depends on securing further contracts, expanding Tpoxx's use, and exploring new biodefense solutions. The company must also prepare for eventual generic competition once its patents expire.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Press Releases
- Analyst Reports (estimates)
- FDA Website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate based on available information. Financial data should be verified through official company filings. AI-based rating is for illustrative purposes and should not be the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About SIGA Technologies Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 1997-09-09 | CEO & Director Dr. Diem Nguyen M.B.A., Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 46 | Website https://www.siga.com |
Full time employees 46 | Website https://www.siga.com | ||
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. Its lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.